Achilles Therapeutics plc (ACHL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHL Stock Price Chart Interactive Chart >
ACHL Price/Volume Stats
|Current price||$1.75||52-week high||$5.65|
|Prev. close||$1.75||52-week low||$1.58|
|Day high||$1.87||Avg. volume||64,438|
|50-day MA||$2.03||Dividend yield||N/A|
|200-day MA||$2.57||Market Cap||68.52M|
Most Popular Stories View All
ACHL Latest News Stream
|Loading, please wait...|
ACHL Latest Social Stream
View Full ACHL Social Stream
Latest ACHL News From Around the Web
Below are the latest news stories about ACHILLES THERAPEUTICS PLC that investors may wish to consider to help them evaluate ACHL as an investment opportunity.
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that United States (US) patent 11,504,398 has been granted. The patent covers the treatment of pat
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics (ACHL - Research Report) today and set a price target of $20.00. The company's shares closed yesterday at $1.79.Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Solid Biosciences. According to TipRanks, Livshits has an average return of 24.8% and a 40.24% success rate on recommended stocks. Achilles Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.See the top stocks recommended by analysts >>The company has a one-year high of $6.88 and a one-year low of $1.72. Currently, Achilles Therapeutics has an average volume of 26.92K.
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9 million supports all planned operations into Q2 2025 - LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the
Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACHL Price Returns